Drug Discovery World

DECEMBER 13, 2022

To this end, the team designed specific antisense oligonucleotides – small pieces of DNA or RNA that can bind to specific RNA molecules. Dr Mariko Taniguchi-Ikeda, Associate Professor in the Department of Clinical Genetics at Fujita Health University Hospital, said: “I have seen patients with FCMD for more than 20 years.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. In addition, they discovered that cladribine, a clinical drug, activates DGKB and inhibits DGAT1. GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 14, 2020

Many drugs fail in clinical trials because of their low blood brain barrier permeability. The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). . Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

MAY 16, 2023

Many developers encounter multi-year delays in programme development because they fail to invest in the development of later stage processes critical to scale-up while collecting early clinical data. What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster?

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. PAXLOVID is currently approved or authorized for conditional or emergency use in more than 70 countries to treat COVID-19.

Marketing 75

Marketing Production Drugs Licensing 75

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding 5.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

APRIL 11, 2024

Treatment of BRCA2-deficient but not wild-type DLD1 cells with BSM-1516 resulted in cell cycle arrest accompanied by DNA damage signalling and accumulation of chromatin-bound RPA32, a marker of ssDNA. It was announced that the next AACR Annual Meeting will take place in Chicago on 25-30 April 2025.

HR 52

HR Antibody In-Vitro DNA 52

Pharmaceutical Technology

NOVEMBER 22, 2022

mRNA vaccines can be made more quickly than traditional vaccine platforms because they are produced using an in vitro synthetic process that does not require the time-consuming growth or removal of cells and proteins. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. The UK Government is behind this effort.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1, The additional 3.7 million treatment courses are planned for delivery by early 2023. .

Drugs 110

Drugs Licensing Licensing Production 110

Drug Discovery World

JANUARY 23, 2023

In cell therapy, regenerative and adoptive immunotherapies continue to bridge the gap between genetic engineering strategies and their clinical application. Being able to differentiate into any cell within the human body, PSCs hold a huge amount of promise within the cell-based therapeutics industry.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

XTalks

MAY 12, 2022

Clinical immunosuppression drugs such as ciclosporin, tacrolimus, sirolimus, prednisone and everolimus are administered to the recovering recipients to prevent transplant rejection. This diagnostic assay works on the principle of in vitro nucleic acid amplification using real-time transcription-mediated amplification (TMA) technology.

In-Vitro 52

In-Vitro DNA Development Genome 52

The Pharma Data

OCTOBER 26, 2021

This kit is an important step forward in Roche and Foundation Medicine’s vision of enabling personalised healthcare for more patients living with cancer by broadening access to CGP and making it essential in clinical decision making in the future. Roche today announced that it has launched the AVENIO Tumor Tissue CGP Kit.

Genome 52

Genome Genomics Research Medicine 52

Pfizer

DECEMBER 20, 2022

Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Tuesday, December 20, 2022 - 04:30pm. In the U.S.,

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

AUGUST 27, 2020

Cancer is a disease of the genome, driven by genetic mutations within a tumour’s DNA. FoundationOne Liquid CDx analyses circulating cell-free DNA from a patient’s blood sample and uses massively parallel sequencing to detect the four main classes of genomic alterations.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

Pfizer

NOVEMBER 23, 2022

Clinical data and real-world evidence for PAXLOVID have shown that it can be an important tool in helping to reduce hospitalizations and deaths in those at increased risk of serious illness from COVID-19,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “As This agreement will supply participating countries up to 3.4

Licensing 40

Licensing Licensing Drugs Manufacturing 40

XTalks

OCTOBER 1, 2020

Dr. Lin received a medical degree from Shanghai Medical University and specialized in hematology after which she began working in the clinical research unit at the university, treating patients with acute leukemia. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

Pharmaceutical Technology

FEBRUARY 20, 2023

If clinical trial participants are representative of the wider disease population, they can help sponsors assess the effectiveness of new and existing therapeutics. of the clinical trial population globally. This may sound obvious, but it is still a major hurdle in drug development. participation of white subjects.

Research 130

Research Clinical Trials Clinical Trials Trials 130

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92